AR111842A1 - Antagonistas de péptido pac1 - Google Patents
Antagonistas de péptido pac1Info
- Publication number
- AR111842A1 AR111842A1 ARP180101446A ARP180101446A AR111842A1 AR 111842 A1 AR111842 A1 AR 111842A1 AR P180101446 A ARP180101446 A AR P180101446A AR P180101446 A ARP180101446 A AR P180101446A AR 111842 A1 AR111842 A1 AR 111842A1
- Authority
- AR
- Argentina
- Prior art keywords
- amino acid
- acid residue
- absent
- neutral
- ala
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Se brindan péptidos que se enlazan a PAC1 humano. Estos péptidos que son antagonistas de PAC1 son útiles en varios trastornos relacionados con PAC1, que incluye el tratamiento y/o la prevención de trastornos de cefalea, lo que incluye migraña, como ser migraña aguda. Reivindicación 1: Un péptido de fórmula (1), o una sal farmacéuticamente aceptable del mismo, X⁰X¹X²X³X⁴X⁵X⁶X⁷X⁸X⁹X¹⁰X¹¹X¹²X¹³X¹⁴X¹⁵X¹⁶X¹⁷X¹⁸X¹⁹X²⁰X²¹X²²X²³X²⁴X²⁵X²⁶X²⁷X²⁸X²⁹X³⁰X³¹X³²X³³X³⁴X³⁵X³⁶X³⁷X³⁸X³⁹X⁴⁰X⁴¹X⁴²X⁴³X⁴⁴ (1), donde X⁰ es Gly, Ser, Gly-Ser-, Ala, Met, Gly-Met-, [Pra], o está ausente, X¹ es Cys si X⁵ es Cys o X¹ es Ser si X⁵ es Ser, Thr, o está ausente, X² es Asp, Glu, o un residuo ácido de aminoácido, o está ausente, X³ es Ala, Pro, Ser, [Aib], o un residuo hidrófobo de aminoácido, o está ausente, X⁴ es Thr, Ser, Val, Tyr, o un residuo neutral, hidrófilo o hidrófobo de aminoácido, o está ausente, X⁵ es Cys si X¹ es Cys o X⁵ es Ser si X¹ es Ser, o está ausente, X⁶ es Lys, [Cit], His, Arg, u otro residuo básico de aminoácido o Gln, Asn, Phe u otro residuo neutral, de aminoácido o Glu u otro residuo ácido de aminoácido, o está ausente, X⁷ es Phe, Tyr, His, o un residuo neutral o hidrófobo de aminoácido, o está ausente, X⁸ es Lys, Arg, o un residuo básico de aminoácido, o está ausente, X⁹ es Lys, Arg, o un residuo básico de aminoácido, o está ausente, X¹⁰ es Ala, Cys, Gly, Leu, Gln, Val, o un residuo neutral de aminoácido, o está ausente, X¹¹ es Ile, Leu, Met, [Aib], o un residuo hidrófobo de aminoácido, o está ausente, X¹² es Asp, Glu, o un residuo ácido de aminoácido, o Ala, Val u otro residuo neural de aminoácido, o está ausente, X¹³ es Asp, Glu, o un ácido, o Ala, Val, [Aib], u otro residuo neutral de aminoácido, o Lys, o está ausente, X¹⁴ es Cys, Ile, Met, Ser, Trp, o está ausente, X¹⁵ es Gln, Ala, Phe, Ile, Leu, Met, Ser, Val, Trp, Tyr u otro aminoácido neutral, o Asp, [Cit], u otro residuo neutral o ácido de aminoácido, o His, Lys u otro residuo básico de aminoácido, o está ausente, X¹⁶ es Lys, Arg, His, u otro residuo básico de aminoácido o Phe, Ile, Leu, [Aib], Gln, Met, Thr, Val, Gly, Asn, [Pra], Trp, Tyr u otro residuo neutral o [hGlu] ácido de aminoácido, o está ausente, X¹⁷ es Ala, Gln, [Aib], Phe, Ile, Leu, Ser, Val, Trp, Tyr, Thr u otro residuo neutral de aminoácido, o [Cit], Lys, Arg, u otro residuo básico de aminoácido o Asp, u otro residuo ácido de aminoácido o está ausente, X¹⁸ es Ala, Leu, [Aib], [Pra], u otro residuo neutral de aminoácido, o Glu u otro residuo ácido de aminoácido o Lys, u otro residuo básico de aminoácido, o está ausente, X¹⁹ es His u otro residuo básico de aminoácido o Ala, Phe, Ile, Leu, Met, Gln, Ser, Val, Trp, Tyr, [Aib], o u otro residuo neutral o hidrófobo de aminoácido, o Lys, Arg u otro residuo básico de aminoácido, o está ausente, X²⁰ es Ala, [Aib], Tyr, u otro residuo neutral o hidrófobo de aminoácido, o His u otro residuo básico de aminoácido, o está ausente, X²¹ es Ala, Met, Ser, Val, [Aib], o un residuo neutral de aminoácido, o está ausente, X²² es Asn, His, Gln, u otro residuo básico o neutral de aminoácido, o Glu u otro residuo ácido de aminoácido, o está ausente, X²³ es Gly, Val, Thr, u otro residuo neutral de aminoácido, o Glu u otro residuo ácido de aminoácido o Lys, u otro residuo básico de aminoácido, o está ausente, X²⁴ está ausente, es Pro, [Pip], [Sar], [Hyp], [DHP] o un residuo neutral de aminoácido, o Arg u otro residuo básico de aminoácido, X²⁵ está ausente, es Ala, Gly, Tyr, [Pra], o un residuo neutral de aminoácido, X²⁶ está ausente, es Asn, Gln, o un residuo neutral de aminoácido, o Leu-Gln-Thr-Ser-Val-, X²⁷ es Ala, Gly, Ser, [Aib], u otro residuo neutral o hidrófilo de aminoácido, o Asp u otro residuo ácido de aminoácido, o está ausente, X²⁸ está ausente, es Val, Thr, u otro residuo neutral o hidrófilo de aminoácido, o Lys u otro residuo básico de aminoácido, X²⁹ está ausente, es APhe, Trp, Tyr, [Aib], o un residuo neutral o hidrófobo de aminoácido, X³⁰ es Lys, [Aib], Ala, [d-Ala], u otro residuo básico o neutral de aminoácido, o Glu u otro residuo ácido de aminoácido, o está ausente, X³¹ es Glu, [Aib], Ala, Ser, Thr, Val, Leu, u otro residuo ácido o neutral de aminoácido, o Lys u otro residuo básico de aminoácido, o está ausente, X³² es Cys, Arg, Leu, Ser, o está ausente, X³³ es la, Phe, Ile, Leu, Ser, Val, [SeMet], Met, [Nle], Cys, u otro residuo hidrófobo de aminoácido, o Glu u otro residuo ácido de aminoácido, o está ausente, X³⁴ es Lys, [Aib], Ala, Leu, Val, u otro residuo básico o neutral de aminoácido, o Glu u otro residuo ácido de aminoácido, o está ausente, X³⁵ es Gln, Phe, Glu, Asn, Thr, [Aib], Ala, Pro, Cys, u otro residuo ácido o neutral de aminoácido, o Arg u otro residuo básico de aminoácido, o está ausente, X³⁶ es Lys, [d-Lys], [Orn], Glu, Gly, Gln, His, Ala, [Aib], [NMeLys], Cys, Arg, Leu, o un residuo básico o neutral de aminoácido, o está ausente, X³⁷ es Lys, Ala, Gln, [Aib], Phe, Arg, o un residuo básico o neutral de aminoácido, o está ausente, X³⁸ está ausente, es Lys, Ala, [Aib], Glu, [Orn], Gln, Gly, [d-Lys], [NMeLys], Phe, Leu, Asn, Arg, Thr, o un residuo ácido básico o neutral de aminoácido, X³⁹ está ausente, es Glu, Ala, [Aib], Leu, Val, u otro residuo ácido o neutral de aminoácido, o Arg u otro residuo básico de aminoácido, X⁴⁰ está ausente, es Phe, [AMEF], Trp,[d-Phe], [hPhe], Tyr, [Aib], [pI-Pheo], o un residuo neutral o hidrófobo de aminoácido, o Glu u otro residuo ácido de aminoácido, X⁴¹ está ausente, es Lys, [NMeLys],[d-Lys], Gln, Glu, His, Ala, [Aib], Leu, Arg, o un residuo básico, o ácido o neutral de aminoácido, X⁴² está ausente, es Ala, Glu, [Aib], Pro, Cys, o un residuo ácido o neutral de aminoácido, X⁴³ está ausente, es Gly, Glu, Ala, [Aib], Asn, Gln, Trp, Cys, u otro residuo neutral o ácido de aminoácido, o His, Arg cu otro residuo básico de aminoácido, X⁴⁴ está ausente, es Lys, His, [d-Lys], [Orn], Ala, Phe, Asn, Gln, Arg, Trp, Tyr un residuo básico o neutral de aminoácido, o fragmentos -Gly-Ser, -Gly-Gly-Gly-Ser, -His-His-His-His-His, o-His- His-His-His-His-His, o Glu u otro aminoácido ácido, donde 11 residuos de aminoácido pueden estar ausentes al mismo tiempo, donde X¹ y X⁵ y puede, opcionalmente, formar enlaces de disulfuro, donde X¹⁴ y X³² y puede, opcionalmente, formar enlaces de disulfuro, donde el residuo del extremo amino pueden estar opcionalmente acetilados y el residuo de extremo carboxi puede estar opcionalmente amidada.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762514440P | 2017-06-02 | 2017-06-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR111842A1 true AR111842A1 (es) | 2019-08-21 |
Family
ID=62685214
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP180101446A AR111842A1 (es) | 2017-06-02 | 2018-05-31 | Antagonistas de péptido pac1 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US11643440B2 (es) |
| EP (1) | EP3630147A2 (es) |
| JP (1) | JP7195281B2 (es) |
| AR (1) | AR111842A1 (es) |
| AU (1) | AU2018275270B2 (es) |
| CA (1) | CA3065115A1 (es) |
| MA (1) | MA48780A (es) |
| TW (1) | TW201920235A (es) |
| UY (1) | UY37753A (es) |
| WO (1) | WO2018222991A2 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7756001B2 (ja) | 2019-06-28 | 2025-10-17 | アムジエン・インコーポレーテツド | 抗cgrp受容体/抗pac1受容体二重特異性抗原結合タンパク質 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| NO812612L (no) | 1980-08-06 | 1982-02-08 | Ferring Pharma Ltd | Enzym-inhibitorer. |
| US4612132A (en) | 1984-07-20 | 1986-09-16 | Chevron Research Company | Modified succinimides |
| US5397772A (en) | 1989-06-29 | 1995-03-14 | The President And Fellows Of Harvard College | Vasodilatory peptides from the salivary gland of the sand fly Lutzomyia longipalpis |
| US5683888A (en) | 1989-07-22 | 1997-11-04 | University Of Wales College Of Medicine | Modified bioluminescent proteins and their use |
| US5292658A (en) | 1989-12-29 | 1994-03-08 | University Of Georgia Research Foundation, Inc. Boyd Graduate Studies Research Center | Cloning and expressions of Renilla luciferase |
| US5331573A (en) | 1990-12-14 | 1994-07-19 | Balaji Vitukudi N | Method of design of compounds that mimic conformational features of selected peptides |
| DK0575319T3 (da) | 1991-03-11 | 2000-07-10 | Univ Georgia Res Found | Kloning og ekspression af Renilla-luciferase |
| US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
| US5480864A (en) | 1993-08-06 | 1996-01-02 | Shiseido Co., Ltd. | Modified maxadilan protein, its preparation and use, and DNA encoding the protein |
| WO1995007463A1 (en) | 1993-09-10 | 1995-03-16 | The Trustees Of Columbia University In The City Of New York | Uses of green fluorescent protein |
| WO1995021191A1 (en) | 1994-02-04 | 1995-08-10 | William Ward | Bioluminescent indicator based upon the expression of a gene for a modified green-fluorescent protein |
| US5463564A (en) | 1994-09-16 | 1995-10-31 | 3-Dimensional Pharmaceuticals, Inc. | System and method of automatically generating chemical compounds with desired properties |
| US5777079A (en) | 1994-11-10 | 1998-07-07 | The Regents Of The University Of California | Modified green fluorescent proteins |
| JPH08333392A (ja) * | 1995-06-05 | 1996-12-17 | Shiseido Co Ltd | 生理活性ポリペプチド類 |
| US6462016B1 (en) * | 1995-10-06 | 2002-10-08 | Shiseido Company, Ltd. | Method for screening agonist or antagonist of the maxadilan receptor participating in vasodilating action, and compound found by the method |
| US5874304A (en) | 1996-01-18 | 1999-02-23 | University Of Florida Research Foundation, Inc. | Humanized green fluorescent protein genes and methods |
| US5804387A (en) | 1996-02-01 | 1998-09-08 | The Board Of Trustees Of The Leland Stanford Junior University | FACS-optimized mutants of the green fluorescent protein (GFP) |
| US5876995A (en) | 1996-02-06 | 1999-03-02 | Bryan; Bruce | Bioluminescent novelty items |
| US5880972A (en) | 1996-02-26 | 1999-03-09 | Pharmacopeia, Inc. | Method and apparatus for generating and representing combinatorial chemistry libraries |
| US6017533A (en) | 1996-04-25 | 2000-01-25 | Shiseido Company, Ltd. | Peptides having specific affinity to pituitary adenylate cyclase activating polypeptide type 1 receptors |
| US5925558A (en) | 1996-07-16 | 1999-07-20 | The Regents Of The University Of California | Assays for protein kinases using fluorescent protein substrates |
| US5976796A (en) | 1996-10-04 | 1999-11-02 | Loma Linda University | Construction and expression of renilla luciferase and green fluorescent protein fusion genes |
| US6458547B1 (en) | 1996-12-12 | 2002-10-01 | Prolume, Ltd. | Apparatus and method for detecting and identifying infectious agents |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| US6232107B1 (en) | 1998-03-27 | 2001-05-15 | Bruce J. Bryan | Luciferases, fluorescent proteins, nucleic acids encoding the luciferases and fluorescent proteins and the use thereof in diagnostics, high throughput screening and novelty items |
| US20020182729A1 (en) * | 2001-01-11 | 2002-12-05 | Dicicco-Bloom Emanuel | Pituitary adenylate cyclase-activating polypeptide (PACAP) is an anti-mitogenic signal for selected neuronal precursors in vivo |
| DE60235013D1 (de) | 2001-07-25 | 2010-02-25 | Facet Biotech Corp | Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab |
| WO2003092716A2 (en) | 2002-05-03 | 2003-11-13 | Neuronova Ab | Therapeutic use of pacap, maxadilan, pacap receptor agonist and/or adcyap1r1 in the treatment of cns disorders |
| BR0315872A (pt) | 2002-10-29 | 2006-07-18 | Us Gov Health & Human Serv | Polipeptìdeos de lutzomyia longipalpis e processos de utilização e método de uso |
| CN101125881A (zh) * | 2007-07-20 | 2008-02-20 | 暨南大学 | 重组pac1受体结抗剂d(25-44)rmmax及其表达方法与应用 |
| WO2009033489A2 (en) * | 2007-09-11 | 2009-03-19 | Glostrup Hospital | Selective pacl inhibitors for use in the treatment of migraine and headaches |
| CN103768588A (zh) | 2008-05-08 | 2014-05-07 | 梅里亚有限公司 | 使用白蛉唾液免疫原的利什曼原虫疫苗 |
| EP2313783A2 (en) | 2008-07-18 | 2011-04-27 | Galderma Research & Development | Pacap signaling pathway modulators for treating inflammatory skin diseases with a neurogenic component, and more particularly rosacea and composition containing them |
| WO2010078469A2 (en) | 2008-12-31 | 2010-07-08 | The Usa As Represented By The Secretary, Department Of Health And Human Services | Sand fly salivary proteins as novel factor xa inhibitors and methods of use |
| JP5447784B2 (ja) | 2009-03-12 | 2014-03-19 | 国立大学法人 鹿児島大学 | マキサディランの部分ペプチドを含む神経因性疼痛の治療剤 |
| CA2797033C (en) | 2010-04-22 | 2021-10-19 | Longevity Biotech, Inc. | Highly active polypeptides and methods of making and using the same |
-
2018
- 2018-05-31 AR ARP180101446A patent/AR111842A1/es unknown
- 2018-05-31 UY UY0001037753A patent/UY37753A/es not_active Application Discontinuation
- 2018-06-01 JP JP2019565520A patent/JP7195281B2/ja active Active
- 2018-06-01 EP EP18733107.9A patent/EP3630147A2/en active Pending
- 2018-06-01 MA MA048780A patent/MA48780A/fr unknown
- 2018-06-01 AU AU2018275270A patent/AU2018275270B2/en active Active
- 2018-06-01 TW TW107119044A patent/TW201920235A/zh unknown
- 2018-06-01 US US16/619,874 patent/US11643440B2/en active Active
- 2018-06-01 CA CA3065115A patent/CA3065115A1/en active Pending
- 2018-06-01 WO PCT/US2018/035597 patent/WO2018222991A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| UY37753A (es) | 2018-11-30 |
| US20210395313A1 (en) | 2021-12-23 |
| JP7195281B2 (ja) | 2022-12-23 |
| MA48780A (fr) | 2020-04-08 |
| AU2018275270B2 (en) | 2024-06-06 |
| EP3630147A2 (en) | 2020-04-08 |
| AU2018275270A1 (en) | 2019-12-12 |
| TW201920235A (zh) | 2019-06-01 |
| CA3065115A1 (en) | 2018-12-06 |
| WO2018222991A3 (en) | 2019-01-31 |
| JP2020522476A (ja) | 2020-07-30 |
| WO2018222991A2 (en) | 2018-12-06 |
| US11643440B2 (en) | 2023-05-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR096162A1 (es) | Péptidos terapéuticos | |
| AR096927A1 (es) | INHIBIDORES POTENTES Y SELECTIVOS DE NaV1.7 | |
| AR064555A1 (es) | Peptido wt1 restringido a hla-a*1101 y composicion farmaceutica que comprende el mismo | |
| EP2214693B1 (en) | Use of melanocortins to treat insulin sensitivity | |
| US20170240595A1 (en) | Melanocortin Receptor Ligands | |
| JPH08510205A (ja) | Yyペプチドのアナログとその用途 | |
| AR088413A1 (es) | INHIBIDORES POTENTES Y SELECTIVOS DE NaV1.3 Y NaV1.7 | |
| WO2010111617A4 (en) | Parathyroid hormone peptides and parathyroid hormone-related protein peptides and methods of use | |
| ME03709B (me) | Fuzijski proteini | |
| JP2016512255A (ja) | インスリン‐インクレチン複合物 | |
| IE57774B1 (en) | Grf analogs | |
| RU2017119773A (ru) | Пептидные антагонисты пептидных гормонов из семейства кальцитонина (cgrp) и их применение | |
| AU2012210565B2 (en) | Human lactoferrin derived peptides and there use | |
| DE60318547T2 (de) | Agonisten des corticotropin-freisetzenden faktor rezeptors 2 | |
| EP0352014A3 (en) | Cyclic grf analogs | |
| WO2012174397A3 (en) | Anti-inflammatory pharmaceutical products | |
| JP2017502003A5 (es) | ||
| AU2006269321A1 (en) | Ligands of melanocortin receptors | |
| AU2012210565A1 (en) | Human lactoferrin derived peptides and there use | |
| JP2017505772A5 (es) | ||
| AR111842A1 (es) | Antagonistas de péptido pac1 | |
| KR930701486A (ko) | Crf (씨이 알 에프) 유사체 | |
| AU2010216383B2 (en) | Analogues of neuropeptide Y having at least one synthetic amino acid substitution | |
| Laurent et al. | A comparison of the leech Theromyzon tessulatum angiotensin I-like molecule with forms of vertebrate angiotensinogens: a hormonal system conserved in the course of evolution | |
| Gagnon et al. | Primary structure of the A chain of human complement-classical-pathway enzyme C1r. N-terminal sequences and alignment of autolytic fragments and CNBr-cleavage peptides |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |